Navigation Links
ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports

DALLAS, August 4, 2011 /PRNewswire/ --


ReportsnReports announces it will carry reports on Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market in its store

A. Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics
The coming decade will see drug delivery technologies become a focal point of competition within the pharmaceutical industry. The line between drug delivery and drug substance will continue to become more elusive in the near future as shown in the analysis in this report, as researchers work to improve drug properties through drug design and molecular modeling.

This Needle-Free Drug Delivery market report takes a look at this aspect of the pharmaceutical marketplace with figures and forecasts for pharmaceutical companies and the companies that supply technology to them. The success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs.

This report looks at that trend and reports current and forecasted revenues for the injectable drug delivery market, segmented into two main categories:

  • Needle-Free Products Market (Including Drug and Technology)
  • Needle-Free Products Market (Technology Only)

Explore the complete report on needle-free drug delivery market.

B. Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends

This report predicts the combined world market for testing and treatment products for Hospital-Acquired Infections (HAI) will reach $10.3 billion in 2015, up from $9 billion in 2010, with higher growth experienced in the testing segment. This type of infection is also known as a nosocomial infection (or more generically healthcare-associated infections).

The following market data is provided in this report:

  • Market for HAI Diagnostics
  • Forecast for HAI Diagnostics to 2015
  • HAI Tests on the Market
  • Market for Diagnostics by Infection Type (C. Diff., MRSA, Pneumonia, Other)
  • Molecular HAI Market vs. Conventional HAI Market, Present and in 2015
  • Geographic Breakdown of Testing (U.S., Europe, Asia, ROW)
  • New Hospital Infection Product Testing Products in the Market
  • Company Profiles
  • Treatment Products on the Market, HAI Antibiotic market Size and Forecast

Both diagnostics and treatment segments have unique circumstances for growth which are discussed in detail in the report. The market has shown an increase of 3% annually with sales increasing from $7.9 billion in 2005. Although the treatment segment will continue to struggle to maintain growth, the testing segment will offset declines beginning in 2012.

The report finds nosocomial infections are an inherent part of any healthcare system and have a 5% infection rate of the 40 million hospital visits a year, causing 100,000 deaths in the U.S. annually. In an effort to decrease the rate of fatality, hospitals are shifting focus towards rapid discovery and treatment of nosocomial infections, driving sales of testing products. This report primarily focuses on bacterial nosocomial infections with some mention of viral infections. The major consideration is given to bacterial nosocomial infections because:

a. they are the most frequent type of infections spread in the hospital setting

b. the practical aspects of diagnosis and therapy are more meaningful based both on medical considerations and on market considerations.

Explore the complete report on hospital-acquired infections (HAI) market.

Other Relevant and Latest Reports on

About Us

ReportsnReports comprises an online market research library of 75,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Follow Us on Twitter:
Our Facebook Page:

Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
Visit Our Market Research Blog

SOURCE ReportsnReports
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ReportsnReports - Daptomycin - Comprehensive Patent Search
2. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
3. ICU Medical Inc. and Health Robotics Announce Compatibility of CytoCare(TM) Robot and CLAVE(R) Needle-Free Connector to Enable Safer Hazardous Drug Handling
4. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
5. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
6. Pantec Biosolutions Selects Oclaro Laser Diode Bars for Transdermal Drug Delivery and Tissue Ablation Systems
7. Scientists engineer nanoscale vaults to encapsulate nanodisks for drug delivery
8. New Drug Delivery System to Improve Cancer Treatment
9. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
10. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
11. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
Post Your Comments:
(Date:11/30/2015)... 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ... immune therapies for solid tumor cancers, announced today that ... director, and the Company welcomes Neil Woodford,s ... recent anonymous internet report on NW Bio.  The Company,s ... Linda Powers stated, "We agree with Mr. Woodford ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Program that includes over 2,000 technical presentations offered in symposia, oral sessions, ... and applied spectroscopy, covers a wide range of applications such as, but not ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
Breaking Biology News(10 mins):